iNGENu CRO, a full-service contract research organization headquartered in Australia, has announced its strategic focus and growing leadership in complex paediatric clinical trials, specifically involving profoundly intellectually and physically disabled children with rare neurodevelopmental conditions.
The Jack Herer Brand, an iconic U.S.-based cannabis company, has announced a strategic partnership with SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specializing in cannabinoid-based medicines.
Chiselbury Publishing is proud to announce the release of "The Brain Always Wins 2," a transformative book co-authored by leading Clinical Sport Psychologist Dr.
A new guide released this month explores how Australian teenagers are leading a shift in menstrual care preferences, with many embracing reusable products like menstrual discs as their first choice.
Contraline, a clinical-stage male contraception company, today announced that participants in the First-in-Human clinical trial of ADAM™ (“The ADAM Study”) have reached a critical milestone, demonstrating both safety and efficacy at the 24-month mark.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2025 and subsequent to the period end.
Etira announced three presentations at the AACR Annual Meeting 2025 featuring new preclinical data on its LIPA-targeting compounds ERX-208 and ERX-315.
